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Edited by Veli-Pekka LehtoAbstract Hepsin, a type II transmembrane serine protease, is
highly upregulated in prostate cancer and promotes tumor pro-
gression and metastasis. We generated a soluble form of hepsin
comprising the entire extracellular domain to show that it eﬃ-
ciently converts single-chain hepatocyte growth factor (pro-
HGF) into biologically active two-chain HGF. Hepsin activity
was potently inhibited by soluble forms of the bi-Kunitz domain
inhibitors HAI-1B (IC50 21.1 ± 2.7 nM) and HAI-2 (IC50
1.3 ± 0.3 nM). Enzymatic assays with HAI-1B Kunitz domain
mutants (R260A and K401A) further demonstrated that inhibi-
tion was due to Kunitz domain-1. The results suggest a functional
link between hepsin and the HGF/Met pathway, which may con-
tribute to tumor progression.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hepsin (also known as TMPRSS1) is a cell surface expressed
chymotrypsin-like serine protease and a member of the family
of type II transmembrane serine proteases (TTSP), which also
include matriptase and enteropeptidase [1]. Hepsin is a 417
amino acid polypeptide [2] composed of a short N-terminal
cytoplasmic tail, a transmembrane region and an extracellular
domain (Arg45–Leu417) composed of the scavenger receptor
cysteine-rich and protease domains. Hepsin zymogen is acti-
vated autocatalytically by cleavage at Arg162–Ile163 [3], form-
ing a heterodimeric enzyme.
The physiological function of hepsin has been elusive. Ex-
cept for coagulation factor VII, no macromolecular substratesAbbreviations: HGF, hepatocyte growth factor; HGFA, HGF activa-
tor; HAI-1, HAI-1B, splice variants of HGFA inhibitor-1; HAI-2,
HGFA inhibitor-2; KD1 and KD2, N- and C-terminal Kunitz domain
of HAI-1B; u-PA, urokinase-type plasminogen activator; t-PA, tissue-
type plasminogen activator; TTSP, type II transmembrane serine
protease
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doi:10.1016/j.febslet.2005.01.085are known and physiologically relevant inhibitors have yet to
be identiﬁed. A role of hepsin in blood coagulation was sug-
gested by Kazama et al. [4] demonstrating that it can activate
coagulation factor VII. However, hepsin-deﬁcient mice were
viable and showed no blood coagulation disorders [5], casting
doubt on the importance of hepsin in normal hemostasis. It is
possible that hepsin may contribute to ﬁbrin formation in
pathologic situations, such as renal cell carcinoma [6], where
the primary initiator of blood coagulation, tissue factor, is ab-
sent. Furthermore, other studies have suggested a functional
link between hepsin and cellular growth. Depending on the tu-
mor cell line and experimental conditions used, hepsin has
been reported to have growth promoting [7] or growth sup-
pressing activity [8].
Hepsin expression is increased in ovarian cancer [9] and in
prostate cancer, where it was identiﬁed as one of the most
highly upregulated genes [10–15]. The expression of hepsin cor-
related with the neoplastic transformation [12], being highest
in tumors of patients with advanced disease and lowest in be-
nign hyperplasia [11,15]. In contrast, one study found that low
expression of hepsin protein correlated with high Gleason
scores and large tumors [13]. Recently, the functional signiﬁ-
cance of hepsin overexpression in prostate cancer was eluci-
dated in an in vivo study by Klezovitch et al. [16],
demonstrating that hepsin promotes prostate cancer progres-
sion and metastasis. Therefore, hepsin may constitute an inter-
esting cancer target and more insight into the substrate/
inhibitor system of hepsin may provide new therapeutic
approaches.
At the epithelial cell surface, hepsin is ideally situated to
interact with components of the extracellular matrix. Serine
proteases, including the TTSP matriptase [17,18] which is
structurally related to hepsin, are known to activate ﬁbrino-
lytic enzymes, matrix metalloproteases and latent forms of
growth factors, such as hepatocyte growth factor (HGF).
HGF is a pleiotropic factor and activates the receptor tyro-
sine kinase Met (reviewed in [19]). HGF is secreted into the
extracellular matrix as an inactive single chain precursor
(pro-HGF) and requires activation cleavage at Arg494–
Val495 to form the biologically competent, disulﬁde-linked
a/b heterodimer [19]. This step is mediated by pro-HGF con-
vertases, including HGF activator (HGFA) [20] and matrip-
tase [21,22]. In turn, the activities of HGFA and matriptase
are regulated by cell surface-expressed Kunitz-type inhibitors,
such as the two HGFA inhibitor splice variants HAI-1 [23,24]blished by Elsevier B.V. All rights reserved.
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bikunin) [25,26]).
In the present study, we demonstrate that hepsin cleaves
pro-HGF with an activity comparable to the potent pro-
HGF convertase HGFA. In addition, we identiﬁed HAI-1B
and HAI-2 as potential physiological regulators of hepsin
activity. The biological implications of these ﬁndings, speciﬁ-
cally in light of co-localization of hepsin and its inhibitors in
prostate cancer, are discussed.2. Materials and methods
2.1. Materials
The chromogenic substrate S2366 was obtained from DiaPharma
Group, Inc. (West Chester, OH), Lys-plasminogen from Haematologic
Technologies Inc. (Essex Junction, VT) and tissue-type plasminogen
activator (t-PA) from Genentech, Inc. (South San Francisco, CA).
Pro-HGF, expressed in Chinese hamster ovary (CHO) cells, was pro-
vided by David Kahn (Genentech). HGFA was produced as described
[22].
2.2. Expression and puriﬁcation of hepsin
The cDNA of full length hepsin, obtained from the I.M.A.G.E.
consortium (ATCC, Manassas, VA), was digested with restriction
endonucleases EcoRI and NotI (New England Biolabs Inc. Beverly,
MA) and inserted in the eukaryotic expression vector pRK5E. A se-
creted His-tagged hepsin cDNA was constructed by fusion of the
cDNA coding for the signal sequence of human HGF (amino acids
Met1–Gly31) with the cDNA coding for the extracellular domain of
human hepsin (Arg45–Leu417). The ﬁnal cDNA construct was
inserted in the eukaryotic expression vector pCMV.PD5. Hepsin
was expressed in a CHO cell transient expression system
and puriﬁed by nickel–nitrilotriacetic acid aﬃnity chromatography
[22].2.3. Expression and puriﬁcation of sHAI-1B, sHAI-1B mutants and
sHAI-2
A soluble form of HAI-1B (sHAI-1B) comprising the extracellular
domain was produced in a CHO cell transient expression system and
puriﬁed as described [22]. Using site-directed mutagenesis, the P1 res-
idues of the N-terminal Kunitz domain (KD1) (P1 residue Arg260)
and the C-terminal Kunitz domain (KD2) (P1 residue Lys401) were
individually changed to Ala and the resulting proteins, sHAI-
1B(R260A) and sHAI-1B(K401A), expressed and puriﬁed as
described [22].
Full length HAI-2 was obtained from a cDNA library derived from
human fetal lung RNA (BD Biosciences Clontech, Palto Alto, CA)
using oligo(dT)/NotI site as a primer and adapator with SalI site for
the second strand. The cDNA was digested with SalI and NotI;
cDNAs greater than 2.8 kb were ligated to pRK5D and single stranded
DNA was generated. Reverse primer (5 0-TTTCTTGAGG-
CACTCCTCCTTG-30) was annealed to the single-stranded cDNA
pool and extended using T7 or T4 DNA polymerase. Escherichia coli
were transformed with the synthesized double-stranded DNA and col-
onies were screened using standard ﬁlter hybridization methods. The
insert size was analyzed by PCR and restriction endonuclease diges-
tion, XbaI. HAI-2 full length clones were identiﬁed and conﬁrmed
by DNA sequencing. A soluble form of HAI-2 (sHAI-2) was produced
by constructing a cDNA coding for the extracellular domain (Ala28–
Lys197) of HAI-2 and addition of a C-terminal His8 tag with a Gly
spacer. The obtained cDNA was then inserted into a baculovirus
expression vector derived from pVL1393 (BD Biosciences Pharmin-
gen). sHAI-2 was expressed in a baculovirus expression system and
puriﬁed by aﬃnity chromatography [27].2.4. Pro-HGF activation and plasminogen activation assays
Pro-HGF (0.3 mg/ml) was incubated in HEPES buﬀer (20 mM
HEPES, pH 7.5, 150 mM NaCl) with 40 nM hepsin or with 40 nM
HGFA for 4 h at 37 C. Analysis by SDS–PAGE of the two-chainHGF generated by hepsin (HGFhepsin) and by HGFA (HGFHGFA)
indicated that >95% of pro-HGF was converted into two-chain
HGF.
Pro-HGF activation assays and 125I-labeling of pro-HGF was car-
ried out as described [22,28]. Brieﬂy, 125I-labeled pro-HGF at
0.05 mg/ml in HEPES buﬀer was incubated with increasing concentra-
tions (0.16–40 nM) of hepsin or HGFA at 37 C. After 4 h, aliquots
were removed and analyzed by SDS–PAGE (4–20% gradient gel)
(Invitrogen) followed by exposure to X-ray ﬁlms. For inhibition stud-
ies, hepsin (15 nM) was incubated in HEPES buﬀer with 1 lM of
sHAI-1B, sHAI-1B(K401A), sHAI-1B(R260A), or sHAI-2 at 37 C.
After 4 h the samples were analyzed by SDS–PAGE.
Plasminogen at 0.12 mg/ml was incubated with 40 nM hepsin or
40 nM t-PA (positive control) in HEPES buﬀer at 37 C. Reaction ali-
quots taken at diﬀerent time points were analyzed by SDS–PAGE.
2.5. Enzyme inhibition assays
Hepsin (0.4 nM) was incubated with increasing concentrations of
inhibitors in 30 mM Tris–HCl, pH 8.4, 30 mM imidazole, 200 mM
NaCl for 30 min. Substrate S2366 (0.2 mM) was added and the change
in absorbance at 405 nm measured on a kinetic microplate reader
(Molecular Devices, Sunnyvale, CA). The IC50 values were calculated
by ﬁtting the data to a four parameter regression curve ﬁtting program
(Kaleidagraph).
2.6. Assays for cell proliferation, migration and Met phosphorylation
Proliferation assays were carried out with the human pancreatic
adenocarcinoma cell line BxPC3 (European Collection of Cell Cul-
tures, Salisbury, UK). Cells were added (10000–15000 cells/well) to
96-well white bottom MT plates (Packard/PerkinElmer, Boston,
MA) and grown in RPMI medium–10% FCS for 24 h. The medium
was replaced with RPMI–0.1% BSA and after 24 h, HGFhepsin and
HGFHGFA in RPMI–0.1% BSA were added. After 72 h, cell prolifer-
ation was quantiﬁed by use of the CellTiter-Glo Luminescent Kit
(Promega, Madison, WI). Luminescence was measured on a Tropix
TR717 luminometer (Berthold, Bad Wildbad, Germany). After sub-
traction of background values (no HGF), the activities of HGFhepsin
and HGFHGFA were expressed as percent of BxPC3 proliferation by
100 ng/ml of an HGF control preparation (obtained from Dr. Ralph
Schwall, Genentech).
Cell migration assays with the breast cancer cell line MDA-MB435
and kinase receptor activation assay with lung carcinoma A549 cells
were carried out as described [27].3. Results
3.1. Proteolytic processing of pro-HGF by hepsin
A soluble form of hepsin encompassing the entire extracellu-
lar domain was expressed in CHO cells. During the puriﬁcation
process hepsin zymogen spontaneously converted into its
two-chain form, most likely due to auto-activation [3]. N-termi-
nal sequencing of the 30 kDa protease domain
(163IVGGRDTSLGR173) conﬁrmed cleavage at the expected
Arg162–Ile163 peptide bond rendering the active enzyme. Hep-
sin converted factor VII zymogen into two-chain factor VIIa
(data not shown), consistent with experiments reported by Kaz-
ama et al. [4] using cell surface expressed hepsin, indicating that
soluble hepsin recapitulates the enzymatic properties of the cel-
lular, full length form. Hepsin activity towards pro-HGF was
examined by measuring conversion of 125I-labeled pro-HGF.
The results showed that pro-HGF was cleaved by hepsin in a
concentration-dependent fashion (Fig. 1A) and comparable to
that of HGFA (Fig. 1B), achieving complete conversion at 4–
13 nM. N-terminal sequencing of the 36 and 39 kDa HGF
b-chains gave identical sequences (495VVNGIPTRTNIG506),
showing that hepsin processed pro-HGF at the expected
Arg494–Val495 peptide bond. Moreover, hepsin lacked the
Fig. 1. Activation of pro-HGF by hepsin. 125I-labeled pro-HGF was
incubated with hepsin or HGFA: 3-fold dilution steps of enzymes,
from 40 nM in lane 2 down to 0.16 nM in lane 7. (A) Hepsin and (B)
HGFA. Lane 1, aliquot at t = 0. (C) Activation of plasminogen by
t-PA and hepsin. 1, Buﬀer at 0.5 h; 2, t-PA at 0.5 h; 3, hepsin at 0.5 h;
4, buﬀer at 5 h; 5, t-PA at 5 h; 6, hepsin at 5 h. The positions of
plasminogen (Plg) and the plasmin heavy chain (h.c.) are indicated.
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In comparison, t-PA eﬃciently processed plasminogen having
about 50% of zymogen already cleaved after 0.5 h (Fig. 1C).Fig. 2. Biological activity of pro-HGF cleaved by hepsin. (A, inset)
Unlabeled pro-HGF was cleaved with hepsin or HGFA and the
products (HGFhepsin and HGFHGFA) analyzed by SDS–PAGE. 1, no
enzyme; 2, HGFhepsin; 3, HGFHGFA. (A) Phosphorylation of Met
receptor with increasing concentrations of HGFhepsin (circles),
HGFHGFA (squares), or to single-chain HGF (diamonds), an uncleav-
able single-chain form of HGF. (B) BxPC3 proliferation with
increasing concentrations of HGFhepsin (ﬁlled bars) and HGFHGFA
(open bars). Average of two independent experiments. (C) MDA-
MB435 migration with increasing concentrations of HGFhepsin (ﬁlled
bars) and HGFHGFA (open bars). Except for 5 ng/ml HGF (n = 2), the
results are the average ± S.D. of three experiments.3.2. Biological activity of HGF generated by hepsin digestion
Unlabeled pro-HGF was completely converted to HGF
with hepsin or HGFA to give HGFhepsin and HGFHGFA,
respectively (Fig. 2A, inset). Both HGF preparations in-
duced similar concentration-dependent increases in Met
phosphorylation, reaching maximal activity at 250 ng/ml
(Fig. 2A). As shown previously [27], an uncleavable single
chain form of HGF had no activity (Fig. 2A). Furthermore,
HGFhepsin eﬃciently promoted proliferation of BxPC3 pan-
creatic cancer cells. The activity was comparable to that of
HGFHGFA in the examined range of 5–100 ng/ml (Fig.
2B). Similar results were obtained in a cell migration assay
with MDA-MB435 cells using a transwell migration system.
The pro-migratory eﬀects of HGFhepsin were concentration-
dependent and indistinguishable from that of HGFHGFA
(Fig. 2C).
3.3. Inhibition of hepsin enzymatic activity by sHAI-1B and
sHAI-2
In an amidolytic assay with the synthetic substrate S2366,
the Kunitz inhibitors sHAI-1B and sHAI-2 potently inhibited
hepsin activity with IC50 values of 21.1 ± 2.7 and 1.3 ± 0.3 nM,
respectively (Fig. 3A). Moreover, mutant sHAI-1B(K401A)
containing a non-functional KD2 was equally potent as wild-
type sHAI-1B (IC50 18.2 ± 3.7 nM), whereas sHAI-
1B(R260A) had <5% of wild-type activity (IC50 > 500 nM)
(Fig. 3A).
In agreement, sHAI-2, wild-type sHAI-1B and sHAI-
1B(K401A) at 1 lM completely inhibited pro-HGF cleavage
(Fig. 3B). In contrast, sHAI-1B(R260A) showed no inhibition
Fig. 3. Inhibition of hepsin enzymatic activity by sHAI-1B and
sHAI-2. (A) Amidolytic assay. Hepsin was incubated with inhibitors
and enzymatic activity towards S2366 was measured. sHAI-1B
(squares), sHAI-1B(R260A) (inverted triangles), sHAI-1B(K401A)
(ﬁlled circles), sHAI-2 (open circles). (B) Pro-HGF activation assay.
125I-labeled pro-HGF was incubated with hepsin and 1 lM of
inhibitors for 4 h at 37 C. 1, aliquot at t = 0; 2, no inhibitor; 3,
sHAI-1B; 4, sHAI-1B(R260A); 5, sHAI-1B(K401A); 6, sHAI-2.
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(Fig. 3B).4. Discussion
This study demonstrates that hepsin, a serine protease highly
upregulated in prostate and ovarian cancer, is a potent activa-
tor of pro-HGF. Therefore, hepsin may contribute to tumor
progression by activating the HGF/Met signalling pathway,
which has been implicated in both prostate [29] and ovarian
cancer [30].
Hepsin proteolytically cleaved pro-HGF at the Arg494–
Val495 peptide bond without any additional cleavage at
Arg424–His425 in Kringle domain 4, a site recognized by fac-
tor XIa and plasma kallikrein [28]. The two-chain HGF gener-
ated by hepsin was fully functional with biological activities
comparable to HGF generated by HGFA. The proteolytic
activity of hepsin towards pro-HGF appears speciﬁc, since it
did not cleave plasminogen, a close structural homolog of
pro-HGF. In support, hepsin has no proteolytic activity to-
wards other serine protease substrates, such as prothrombin,
protein C, factor X and factor IX [4]. The soluble hepsin used
in our experiments consisted of the entire extracellular non-
catalytic and the protease domains and, thus, contained the
essential structural elements which determine substrate speci-
ﬁcity (active site region and exosites). Therefore, we presumethat soluble hepsin recapitulates substrate and inhibitor speci-
ﬁcity of the surface-expressed form. This notion is supported
by our ﬁnding that soluble hepsin activated zymogen factor
VII similar to cell-surface expressed hepsin [4] and by studies
using diﬀerent recombinant or puriﬁed forms of the related
TTSP matriptase [21,22,24,31,32].
A recent in vivo study demonstrated that overexpression of
hepsin in a mouse model of non-metastasizing prostate cancer
results in cancer progression and metastasis [16]. The observed
disruption of basement membrane architecture and the disor-
ganization of epithelial structure could, at least in part, be
due to generation of active HGF by hepsin. HGF is known
to activate proteolytic pathways [e.g., urokinase-type plasmin-
ogen activator (u-PA), u-PA receptor, and matrilysin] leading
to basement membrane degradation and cell–cell dissociation
[33–35]. For instance, it was shown that HGF-mediated matri-
lysin activation resulted in E-cadherin cleavage and disruption
of cell–cell adhesion leading to increased invasive potential of
LNCap prostate cancer cells [35]. It remains to be seen whether
hepsin itself is capable of degrading basement membrane com-
ponents, such as laminin 5 or collagen IV.
HAI-1B, HAI-1 and HAI-2 are epithelial cell surface inhib-
itors and, as such, are ideally located to regulate the enzymatic
activity of epithelial cell-expressed TTSPs and other cell sur-
face associated serine proteases. Here, we demonstrate that
both sHAI-1B and sHAI-2 are potent inhibitors of hepsin.
Moreover, P1 residue-directed mutagenesis experiments dem-
onstrated that inhibition is mediated by KD1 of sHAI-1B.
Thus, hepsin, matriptase and HGFA not only have compara-
ble pro-HGF converting activities but are also inhibited by
sHAI-1B with equal potencies (16–30 nM) in a KD1-speciﬁc
fashion [22]. The role of HAI-2 Kunitz domains was not spe-
ciﬁcally addressed in our study. For most of its target enzymes,
HAI-2 utilizes both the N-and C-terminal Kunitz domains
[26]. Whether or not this also applies to the inhibition of hep-
sin remains to be seen.
Both HAI-1 splice variants and HAI-2 are expressed in nor-
mal prostate [22,36] and HAI-1 antigen is localized to the epi-
thelial cell type in normal prostate [36]. In prostate cancer,
hepsin expression is strongly upregulated (>7-fold) [10–15],
whereas expression of HAI-1 and HAI-2 increases only slightly
(about 1.5-fold) according to gene expression results reported
by Welsh et al. [10]. As a consequence, hepsin enzymatic activ-
ity in prostate cancer may be inadequately controlled and
could lead to enhanced pro-HGF processing and tumor pro-
gression. Similar imbalances of pro-HGF convertase/inhibitor
systems have been described for matriptase/HAI-1 in ovarian
cancer [37] and HGFA/HAI-1 and HGFA/HAI-2 in renal cell
carcinoma [38]. The upregulated expression of hepsin in some
of these cancers suggests that certain convertase/inhibitor
systems comprise multiple enzymes and therefore increased
enzyme/inhibitor ratios could magnify the consequences for
malignancy.
In conclusion, the results suggest a functional link between
hepsin and the HGF/Met pathway, which may contribute to
tumor progression. The ﬁnding that HAI-1B and HAI-2 are
potent inhibitors of hepsin may provide new treatment ap-
proaches. For example, the functional Kunitz domains of
HAI-1B or HAI-2 could serve as scaﬀolds for generating more
speciﬁc and/or more potent enzyme inhibitors by use of phage
display technology, which has been successfully applied to
other Kunitz domain scaﬀolds.
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